Recently, GlaxoSmithKline (GSK) announced that the expanded study of its recombinant herpes zoster vaccine "Xin'anlishi" has achieved positive interim results
.
The results showed that the vaccine provided at least 10 years of protection
against shingles after the initial vaccination.
Currently, this expanded study is ongoing and will continue to evaluate the long-term efficacy, immunogenicity and safety
of the vaccine.
It is known that shingles is caused
by reactivation of the varicella-zoster virus.
As we age, the immune system loses its ability to produce a strong and effective immune response, increasing the risk of shingles, a condition that causes unbearable pain that some patients experience after the rash wears off, a nerve pain called postherpetic neuralgia that can last for months or even years
.
Vaccination against herpes zoster is an effective measure to prevent the onset of
shingles.
In the Chinese market, the shingles vaccine industry is still an emerging industry, and there are only two shingles vaccines approved on the market, namely Merck's Zostavax in 2006 and GlaxoSmithKline's Shingrix
, which was approved for marketing in 2017.
According to the relevant charging standards of medical institutions across the country, the current reference price of Shingrix shingles vaccine is generally between 1500-1800 yuan / needle, and the price in first- and second-tier cities is higher
.
Industry analysts believe that with the aging of the population and the increase in the number of new cases of shingles, the future growth space of China's shingles vaccine market will continue to expand
.
In fact, according to industry assessment analysis, China's shingles vaccine market is expected to grow at a CAGR of 103.
8% from 2021 to 2025 to RMB10.
8 billion in 2025 and further grow at a CAGR of 21.
1% from 2025 to 2030 to RMB28.
1 billion
in 2030.
At present, out of optimism about the market prospects, many local companies in China, including Luzhu Biotechnology, Baig Biotechnology, Wantai Biotechnology, Watson Biotechnology, Zhifei Biotechnology, etc.
are accelerating the development of shingles vaccine
.
It is understood that shingles vaccines are divided into three types, namely live attenuated vaccines, recombinant vaccines and messenger RNA (mRNA) vaccines, and these types are involved in
enterprises.
Among them, the company with faster development progress is Baig Biotechnology, which obtained the clinical trial approval of live attenuated herpes zoster vaccine as early as June 26
, 2014.
In April 2022, the company received the "Notice of Acceptance" for the vaccine marketing authorization application, and has officially entered the stage
of application for marketing.
At the end of September, Baig Biotech said in an investor survey that the company's clinical trial and production site verification of live attenuated herpes zoster vaccine have been completed, and it is currently waiting for a reply
from the Drug Evaluation Center of the State Food and Drug Administration.
In addition, Luzhu Biotechnology, a shareholding company of Saisheng Pharmaceutical, has also made rapid
progress in the research and development of shingles vaccines.
According to the company's announcement, in April this year, its "recombinant herpes zoster vaccine (CHO cells)" project has entered the second phase of clinical trials
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
